Yahoo Finance • 19 days ago
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, announced today that members of its senior... Full story
Yahoo Finance • 28 days ago
IO Biotech, Inc. (NASDAQ:IOBT) is one of the 11 Low Price High Volume Stocks to Buy According to Analysts. On August 15, H.C. Wainwright reiterated a Buy rating on IO Biotech, Inc. (NASDAQ:IOBT), keeping its price target at $14. Emily Bod... Full story
Yahoo Finance • last month
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume. [unusualvolume] UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT VMAR [https://www.chartmill.com/stock/quote/VMAR/profile]... Full story
Yahoo Finance • last month
Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. [topmovers] TOP GAINERS TICKER CHANGE CO... Full story
Yahoo Finance • last month
Discover the stocks with unexpected trading volume in today's session on the US markets. [unusualvolume] UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT ADD [https://www.chartmill.com/stock/quote/ADD/profile] -29.04% 56.82M s... Full story
Yahoo Finance • last month
Looking for insights into the US markets in the middle of the day on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT... Full story
Yahoo Finance • last month
The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today. [postmarket] AFTER HOURS GAINERS TICKER CHANGE COMMENT ANY [https://www.chartmill.com/stock/qu... Full story
Yahoo Finance • last month
Curious about what's happening in today's session? Check out the latest stock movements and price changes. [topmovers] GAINERS TICKER CHANGE COMMENT EQ [https://www.chartmill.com/stock/quote/EQ/profile] 77.82% Positive ma... Full story
Yahoo Finance • last month
Here are the top movers in Monday's session, showcasing the stocks with significant price changes. [topmovers] GAINERS TICKER CHANGE COMMENT EQ [https://www.chartmill.com/stock/quote/EQ/profile] 87.56% With a 87.56% surge... Full story
Yahoo Finance • last month
NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Wang & Lee Group Inc. 319,475,864 0.069 0.0559 0.0592 +0.0134 Entero The... Full story
Yahoo Finance • last month
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. [premarket] PRE-MARKET GAINERS TICKER CHANGE COMMENT E... Full story
Yahoo Finance • last month
IO Biotech Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients treated with pembrolizumab monotherapy, HR=0.77 (CI 0.58-... Full story
Yahoo Finance • 2 months ago
* IO Biotech (NASDAQ:IOBT [https://seekingalpha.com/symbol/IOBT]) filed a prospectus for the offer and sale of 4.22M shares of common stock by the selling stockholders. * This prospectus is not an offer to sell these securities. *... Full story
Yahoo Finance • 4 months ago
NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, announced today that Mai-Britt Zocca, PhD, t... Full story
Yahoo Finance • 4 months ago
H.C. Wainwright raised the firm’s price target on IO Biotech (IOBT) to $14 from $12 and keeps a Buy rating on the shares following the Q1 report. The firm cites lower than expected operating expenses for the target increase. The analyst sa... Full story
Yahoo Finance • 4 months ago
Primary endpoint of pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine in patients with advanced melanoma still expected to readout in third quarter of 2025Data presented at recent congresses reinforc... Full story
Yahoo Finance • 5 months ago
NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that one of its scientific... Full story
Yahoo Finance • 6 months ago
• New non-clinical data strengthens evidence of contributions of IO102 and IO103 to tumor growth control through target specific T-cell activation, offering a distinct and complementary approach to checkpoint inhibitors • New preclinical d... Full story
Yahoo Finance • 7 months ago
Preparations for submission of a Biologics License Application (BLA) for Cylembio® (imsapepimut and etimupepimut, adjuvanted) to FDA by year end 2025 remain on track. The trial completed enrollment in December 2023 ahead of plan with 407 p... Full story
Yahoo Finance • 7 months ago
• Findings support the development of a novel peptide vaccine targeting the immunosuppressive effects of Transforming Growth Beta (TGF-β) in solid tumors NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-... Full story